References

10.1038/s41380-023-01949-9

10.1038/s41380-023-01949-9 · External reference

Deconstructing Cognitive Impairment in Psychosis With a Machine Learning Approach

10.1001/jamapsychiatry.2024.3062 · 2025 · External reference

10.1038/s41398-023-02718-6

10.1038/s41398-023-02718-6 · External reference

Antipsychotic Drugs and Cognitive Function

10.1001/jamapsychiatry.2024.2890 · 2025 · External reference

The genetics of cognition in schizophrenia

2024 · External reference

10.1016/j.eclinm.2023.102135

10.1016/j.eclinm.2023.102135 · External reference

Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis

10.1176/appi.ajp.20240260 · 2025 · External reference

A focus on valproate and cognitive deficits in Bipolar Disorders: A mini-review

10.1016/j.jad.2019.08.008 · 2020 · External reference

Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set

10.1007/s00406-017-0787-9 · 2018 · External reference

10.1176/appi.ajp.2013.12101339

10.1176/appi.ajp.2013.12101339 · External reference

10.1093/schbul/sbab090

10.1093/schbul/sbab090 · External reference

10.1016/j.schres.2008.03.024

10.1016/j.schres.2008.03.024 · External reference

10.1093/bioinformatics/btad577

10.1093/bioinformatics/btad577 · External reference

An original pharmacoepidemiological– pharmacodynamic method: application to antipsychotic-induced movement disorders

10.1111/bcp.13145 · 2017 · External reference

10.1038/s41398-025-03582-2

10.1038/s41398-025-03582-2 · External reference

XGBoost: A Scalable Tree Boosting System

2016 · External reference

10.1016/j.biopsych.2023.04.004

10.1016/j.biopsych.2023.04.004 · External reference

10.1016/j.neuropharm.2019.107704

10.1016/j.neuropharm.2019.107704 · External reference

10.1093/schbul/sbr189

10.1093/schbul/sbr189 · External reference

Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2/D3 antagonism, D2/D3 partial agonism and placebo

10.1038/s41380-025-03116-8 · 2025 · External reference

Cognitive Effects of a Single Dose of Atypical Antipsychotics in Healthy Volunteers Compared With Placebo or Haloperidol

10.1097/jcp.0b013e318272d10c · 2012 · External reference

10.1016/j.schres.2006.03.033

10.1016/j.schres.2006.03.033 · External reference

10.1016/j.brainres.2015.11.024

10.1016/j.brainres.2015.11.024 · External reference

10.1038/sj.npp.1301636

10.1038/sj.npp.1301636 · External reference

Selective 5HT3 antagonists and sensory processing: a systematic review

10.1038/s41386-021-01255-4 · 2022 · External reference

10.1523/jneurosci.22-21-09185.2002

10.1523/jneurosci.22-21-09185.2002 · External reference

10.1073/pnas.2318641121

10.1073/pnas.2318641121 · External reference

10.1523/jneurosci.1371-20.2021

10.1523/jneurosci.1371-20.2021 · External reference

Enhancement of gamma activity after selective activation of dopamine D4 receptors in freely moving rats and in a neurodevelopmental model of schizophrenia

10.1007/s00429-013-0607-6 · 2014 · External reference

Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease

10.1111/ejn.13357 · 2017 · External reference

10.1016/j.biopsych.2011.02.036

10.1016/j.biopsych.2011.02.036 · External reference

10.1038/s41398-022-02249-6

10.1038/s41398-022-02249-6 · External reference

Anticholinergic Medication Burden–Associated Cognitive Impairment in Schizophrenia

10.1176/appi.ajp.2020.20081212 · 2021 · External reference

The effect of scopolamine on memory and attention: a systematic review and meta-analysis

2025 · External reference

10.1176/appi.ajp.161.1.116

10.1176/appi.ajp.161.1.116 · External reference

The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials

10.1176/appi.ajp.20240076 · 2025 · External reference